AbbVie Strikes Deal With Lupin for Blood Cancer Program

AbbVie closed out 2018 by striking a nearly $1 billion licensing deal for India-based Lupin Ltd.’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.